Study on detection and clinical significance of CD33+HLA-DR-MDSCs cells in hepatocellular carcinoma
10.3969/j.issn.1000-484X.2015.11.017
- VernacularTitle:肝细胞癌患者外周血CD33＋HLA-DR-MDSCs的监测及其临床意义
- Author:
Yongxiang YI
;
Jian WANG
;
Tong ZHUANG
;
Xiang WANG
;
Jianbo HAN
;
Liang ZHAO
;
Yufeng ZHANG
- Publication Type:Journal Article
- Keywords:
Hepatocellular carcinoma;
Immune function;
Myeloid derived suppressor cells
- From:
Chinese Journal of Immunology
2015;(11):1520-1523
- CountryChina
- Language:Chinese
-
Abstract:
Objective:The purpose of this study is to evaluate the frequency of MDSCs in peripheral blood of hepatocellular carcinoma patients and to investigate the clinical significance of change of MDSCs in the peripheral blood and provide new ways for e-valuating immune state and prognosis of hepatocellular carcinoma patients.Methods: Blood samples were obtained from 62 patients with HCC and 20 healthy donors.The phenotype of CD3,CD4,CD33,HLA-DR and Th1,Th2 immune subsets in peripheral blood of each group were observed by FCM methods.Results:There were statically different frequencies in the peripheral blood between hepato-cellular carcinoma and healthy control group,which the proportion of total CD3+T lymphocytes and CD3+CD4+T cells were lower and the proportion of CD33+HLA-DR-MDSCs was higher in hepatocellular carcinoma patients.( P<0.05 ).The increase of percentage of MDSCs was greater in patients at Stage C and D than in patients at stage A and B.Conclusion:The Th1/Th2 ratio in the PBMC were of imbalance and MDSCs was significantly increased in peripheral blood of hepatocellular carcinoma patients.The increase of MDSCs was significantly correlated with clinical stage.CD33+HLA-DR-MDSCs may play an important role in prediction in prognosis and tumor immune status of hepatocellular carcinoma.
